According to the latest news on April 16th, MSD and Prometheus Biosciences, Inc. announced that the two companies have signed a final agreement. According to the agreement, MSD, through its subsidiaries, has agreed to acquire TL1A antibody pioneer Prometheus for $200 per share in cash, with a total equity value of approximately $10.8 billion (approximately 74 billion RMB). The transaction is expected to be completed in the third quarter of 2023. | 
